- Home
- SRTS vs EPIX Comparison
SRTS vs EPIX Comparison
Compare SRTS & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- EPIX
- Stock Information
- Founded
- SRTS 2010
- EPIX 2009
- Country
- SRTS United States
- EPIX Canada
- Employees
- SRTS N/A
- EPIX N/A
- Industry
- SRTS Medical/Dental Instruments
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- EPIX Health Care
- Exchange
- SRTS Nasdaq
- EPIX Nasdaq
- Market Cap
- SRTS 77.9M
- EPIX 75.9M
- IPO Year
- SRTS 2016
- EPIX N/A
- Fundamental
- Price
- SRTS $4.16
- EPIX $1.72
- Analyst Decision
- SRTS Strong Buy
- EPIX Hold
- Analyst Count
- SRTS 3
- EPIX 3
- Target Price
- SRTS $11.67
- EPIX $2.00
- AVG Volume (30 Days)
- SRTS 56.1K
- EPIX 53.1K
- Earning Date
- SRTS 08-07-2025
- EPIX 08-04-2025
- Dividend Yield
- SRTS N/A
- EPIX N/A
- EPS Growth
- SRTS N/A
- EPIX N/A
- EPS
- SRTS 0.11
- EPIX N/A
- Revenue
- SRTS $39,488,000.00
- EPIX N/A
- Revenue This Year
- SRTS $4.33
- EPIX N/A
- Revenue Next Year
- SRTS $31.55
- EPIX N/A
- P/E Ratio
- SRTS $38.07
- EPIX N/A
- Revenue Growth
- SRTS 24.75
- EPIX N/A
- 52 Week Low
- SRTS $4.01
- EPIX $1.40
- 52 Week High
- SRTS $9.33
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- SRTS 28.08
- EPIX 51.31
- Support Level
- SRTS $4.45
- EPIX $1.68
- Resistance Level
- SRTS $4.81
- EPIX $1.75
- Average True Range (ATR)
- SRTS 0.19
- EPIX 0.04
- MACD
- SRTS -0.05
- EPIX 0.00
- Stochastic Oscillator
- SRTS 0.00
- EPIX 62.50
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.